Serine/threonine-protein kinase 4
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Serine/threonine-protein kinase 4 as ChEMBL target CHEMBL4598, mapped to UniProt Q13043. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Serine/threonine-protein kinase 4 matters
Serine/threonine-protein kinase 4 is reviewed as Serine/threonine-protein kinase 4 (UniProt Q13043); the current evidence base includes 10 approved drugs, 1821 compounds, and 323 assays, with lead potency reaching pChEMBL 9.7.
Serine/threonine-protein kinase 4 Sequence length is 487 aa.
Review this target as Serine/threonine-protein kinase 4, mapped to UniProt Q13043. Sequence length is 487 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 10 approved drugs, 1821 compounds, and 323 assays for this target. The dominant activity type is IC50. CHEMBL388978 is the current potency anchor at pChEMBL 9.7.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Serine/threonine-protein kinase 4 matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt Q13043, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
9.7 | EC50 | — |
|
|
No preferred name
CHEMBL388978
|
9.7 | Kd | — |
|
|
No preferred name
CHEMBL388978
|
9.0 | IC50 | — |
|
|
No preferred name
CHEMBL603469
|
8.5 | Kd | Clinical |
|
|
No preferred name
CHEMBL4116008
|
8.4 | IC50 | Clinical |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
MIDOSTAURIN
CHEMBL608533
|
2017 |
|
|
NERATINIB
CHEMBL180022
|
2017 |
|
|
NINTEDANIB
CHEMBL502835
|
2014 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
CRIZOTINIB
CHEMBL601719
|
2011 |
|
|
SUNITINIB
CHEMBL535
|
2006 |